Novel THP-1 Cell Lines for Blood Cancer Research

BACKGROUND

A team of researchers from the University of Calgary have developed five homozygous knock-out cancer cell lines developed on the background of the THP-1 leukemic monocyte. These cell lines may be used as a tool in blood cancer and immunological research, and for screening potential therapeutic candidates. The genotypes are summarized below.

 

GENOTYPES

  • Target gene: NLRP3 (NOD-like receptor containing pyrin 3)
    • Cell line: THP-1 Monocyte
    • Organism: Human
    • Gene editing method: CRISPR/CAS9
    • Parental cell line: ATCC TIB-202
  • Target gene: CASPR 4 (Caspase 4)
    • Cell line: THP-1 Monocyte
    • Organism: Human
    • Gene editing method: CRISPR/CAS9
    • Parental cell line: ATCC TIB-202
  • Target gene: GSDMD (Gasdermin-D)
    • Cell line: THP-1 Monocyte
    • Organism: Human
    • Gene editing method: CRISPR/CAS9
    • Parental cell line: ATCC TIB-202
  • Target gene: ERN1 (Serine/ threonine protein kinase/endonuclease IRE, ERN1)
    • Cell line: THP-1 Monocyte
    • Organism: Human
    • Gene editing method: CRISPR/CAS9
    • Parental cell line: ATCC TIB-202
  • Target gene: AIM2 (Absent in Melanoma 2)
    • Cell line: THP-1 Monocyte
    • Organism: Human
    • Gene editing method: CRISPR/CAS9
    • Parental cell line: ATCC TIB-202

 

AREAS OF APPLICATION 

  • Blood cancer research
  • Immunology research
  • Drug screening

 

PUBLICATIONS AND RESOURCES

Learn more about tech transfer

Contact Us

Contact our team to discuss the benefits of commercialization and licensing through Innovate Calgary.